MARKHAM, ON, Feb. 29, 2012 /CNW/ - Cytochroma today announced that Dr. Charles W. Bishop, Cytochroma's President and Chief Executive Officer, will present a corporate overview at the Cowen and Company 32nd Annual Health Care Conference. This presentation is scheduled at 2:00 PM ET on Monday, March 5, 2012 at the Boston Marriott Copley Place.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stage development.
For further information:
Please visit www.cytochroma.com.
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
Robert Stanislaro (FTI Consulting)
Tel: +1 (212) 850-5657